Bank of Hawaii Sells 8,739 Shares of Natera, Inc. $NTRA

Key Points

• Bank of Hawaii reduced its holdings in Natera, Inc. by 27.3%, owning 23,293 shares worth $3,294,000 as of the latest SEC filing.
• Natera reported a quarterly loss of ($0.74) EPS, missing estimates, but achieved a revenue of $546.60 million, surpassing expectations of $476.84 million.
• Wall Street analysts generally hold a positive outlook on Natera, with a consensus rating of "Buy" and an average price target of $193.19.

Bank of Hawaii lessened its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 27.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,293 shares of the medical research company's stock after selling 8,739 shares during the period. Bank of Hawaii's holdings in Natera were worth $3,294,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. LRI Investments LLC purchased a new position in shares of Natera in the 4th quarter worth approximately $29,000. Bank of Jackson Hole Trust purchased a new position in Natera in the first quarter valued at approximately $29,000. Rakuten Securities Inc. lifted its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the last quarter. TCTC Holdings LLC lifted its stake in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the last quarter. Finally, ORG Partners LLC purchased a new position in Natera in the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on NTRA. Barclays reiterated an "overweight" rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada upped their price objective on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Cowen reiterated a "buy" rating on shares of Natera in a research note on Friday, August 8th. Piper Sandler reiterated an "overweight" rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Buy" and a consensus target price of $193.19.

Insider Activity

In other news, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares of the company's stock, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 6,111 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $157.10, for a total transaction of $960,038.10. Following the completion of the transaction, the chief executive officer directly owned 179,071 shares in the company, valued at approximately $28,132,054.10. The trade was a 3.30% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 58,705 shares of company stock worth $8,743,776. Company insiders own 5.63% of the company's stock.

Natera Stock Up 3.0%

NTRA stock traded up $4.84 during mid-day trading on Thursday, reaching $167.88. 842,708 shares of the company traded hands, compared to its average volume of 1,571,946. Natera, Inc. has a 52-week low of $110.57 and a 52-week high of $183.00. The company has a fifty day moving average price of $154.48 and a 200-day moving average price of $154.05.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.